NIH SBIR Award
The National Institutes of Health (NIH) awarded a phase I grant to Tango in January 2021. This award will support a collaborative effort that generates recombinant antibodies and antibody-like reagents for 6 SARS-CoV-2 viral proteins. These reagents will aid scientists in understanding the function of these viral proteins inside infected cells. Such information may lead to the identification of new drug targets.
Tango publishes work on SARS-CoV-2 virus
Tango scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and the S1 spike subunit, with affinities ranging from 3 to 14 nM as measured by bio-layer interferometry. All four monobodies successfully bound the RBD after overexpression in Chinese hamster ovary (CHO) cells as fusions to the Fc domain of human IgG1. The paper was published February 5, 2021 in the peer-reviewed journal, New Biotechnology, and can be found below.
NIH STTR award
In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
Tango was nominated as a finalist for the best start-up or emerging company. Named “one of the top 8 bioscience start-ups in 2019.”
Brian Kay at the Tango booth.